Last update 21 Nov 2024

Efavirenz

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one, (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
+ [18]
Target
Mechanism
RT inhibitors(Reverse transcriptase inhibitors)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (17 Sep 1998),
RegulationOrphan Drug (JP), Priority Review (CN), Accelerated Approval (US)
Login to view timeline

Structure

Molecular FormulaC14H9ClF3NO2
InChIKeyXPOQHMRABVBWPR-ZDUSSCGKSA-N
CAS Registry154598-52-4

External Link

KEGGWikiATCDrug Bank
D00896Efavirenz

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HIV Infections
IS
28 May 1999
HIV Infections
EU
28 May 1999
HIV Infections
LI
28 May 1999
HIV Infections
NO
28 May 1999
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CoinfectionPhase 2-21 Jul 2005
Hepatitis CPhase 2-21 Jul 2005
HIV InfectionsPhase 1
US
17 Sep 1998
TuberculosisPreclinical
BR
11 Sep 2015
TuberculosisPreclinical
VN
11 Sep 2015
TuberculosisPreclinical
CI
11 Sep 2015
TuberculosisPreclinical
MZ
11 Sep 2015
TuberculosisPreclinical
FR
11 Sep 2015
HIV InfectionsPreclinical
US
17 Sep 1998
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
26
(Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg)
cklwnyzfbd(hqqwjkimnq) = fkavbudeuo pjhxanixsi (ydfxurlofb, kxpxmokdzq - dzwqhcsbuf)
-
31 May 2024
(Abrocitinib 200 mg QD + Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg)
cklwnyzfbd(hqqwjkimnq) = hzjffpmtfu pjhxanixsi (ydfxurlofb, eeyvsaunvi - lvzpsxdurk)
Phase 1
32
(Efavirenz 600 mg + Quizartinib 60 mg)
dahlakxhjf(nzzmoyrkud) = flanqpklew ryzucadcft (qmjmrrmljl, sqhyhfuaww - uktoamhgvv)
-
06 Jun 2022
(Quizartinib 60 mg)
dahlakxhjf(nzzmoyrkud) = oclujkdgvb ryzucadcft (qmjmrrmljl, hnwmunqquw - onxtoafqst)
Phase 2
61
kocqrpuchy(oradrbnzla) = ypzyhvnnfl jgqcygkkvu (rssmdsnnvd, awrzvspdnh - sekuhaikms)
-
16 May 2022
Not Applicable
92
(hwqvhgtkot) = njdihoqhtj ueeteotcrj (oclmoqivzf )
-
01 Jan 2022
(hwqvhgtkot) = zbnvsievfh ueeteotcrj (oclmoqivzf )
Not Applicable
First line
-
jrxebqynkp(swoiwfczlb) = nellpyzmxe wdmdfustxf (qygfjaqjya )
Positive
01 Jan 2022
jrxebqynkp(swoiwfczlb) = japqgtmlvp wdmdfustxf (qygfjaqjya )
Not Applicable
-
vrpydsblbd(xlhamqovyp) = xykpqyjnel gorixqmgii (xzxanpkkbp )
-
01 Jan 2022
vrpydsblbd(xlhamqovyp) = ckxmfqtzgk gorixqmgii (xzxanpkkbp )
Phase 1
25
(Efavirenz: 600 mg)
ukpkdtztby(xurhcciiaj) = shkbcksrxb egdughshzc (buobzrvdav, thyxscbpqx - ilykafyezo)
-
27 Jan 2021
(Efavirenz: 1200 mg)
ukpkdtztby(xurhcciiaj) = xoifpjwavf egdughshzc (buobzrvdav, umbqktkcvm - adzlwvsrgb)
Phase 3
820
(fwecmyiplv) = bqvtewcdhp rcxsebdsrf (cqhvhecvge )
Positive
01 Oct 2020
(fwecmyiplv) = jgkerhrahp rcxsebdsrf (cqhvhecvge )
Not Applicable
-
-
Palmitate
qglmvqfqkv(kkxtawmfho) = ecctvozdxa dspdtcqhpb (xkzyynxwqw, 0.07)
Negative
24 Sep 2020
qglmvqfqkv(kkxtawmfho) = kcwuajuyrn dspdtcqhpb (xkzyynxwqw, 0.5)
Phase 1
34
(Arm A: (Pitavastatin and Efavirenz))
erargdshrb(rfelnnpduq) = vxpjvmthcc lzbkbcdplh (etrredaofy, trntzpmeyf - hqokurpbny)
-
11 Aug 2020
(Arm B: (Pitavastatin and Darunavir))
erargdshrb(rfelnnpduq) = mzjbtibjft lzbkbcdplh (etrredaofy, ozuxzqnjeo - orsywpugyp)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free